Terms: = Leukemia AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Clinical Outcome
9 results:
1. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.
Leung GMK; Zhang C; Ng NKL; Yang N; Lam SSY; Au CH; Chan TL; Ma ESK; Tsui SP; Ip HW; So JCC; Ng MHL; Cheng KCK; Wong KF; Siu LLP; Yip SF; Lin SY; Lau JSM; Luk TH; Lee HKK; Lau CK; Kho B; Kwong YL; Leung AYH
Am J Hematol; 2019 Jun; 94(6):650-657. PubMed ID: 30900772
[TBL] [Abstract] [Full Text] [Related]
2. clinical impact of SNP of P53 genes pathway on the adult AML patients.
Abdel Hamid TM; El Gammal MM; Eibead GT; Saber MM; Abol Elazm OM
Hematology; 2015 Jul; 20(6):328-35. PubMed ID: 25232917
[TBL] [Abstract] [Full Text] [Related]
3. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Sun LL; Wu JY; Wu ZY; Shen JH; Xu XE; Chen B; Wang SH; Li EM; Xu LY
Int J Cancer; 2015 Mar; 136(6):E569-77. PubMed ID: 25220908
[TBL] [Abstract] [Full Text] [Related]
4. mdm2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.
Willander K; Ungerbäck J; Karlsson K; Fredrikson M; Söderkvist P; Linderholm M
Eur J Haematol; 2010 Sep; 85(3):251-6. PubMed ID: 20491880
[TBL] [Abstract] [Full Text] [Related]
5. Lack of association between the mdm2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.
Kaderi MA; Mansouri M; Zainuddin N; Cahill N; Gunnarsson R; Jansson M; Kimby E; Aleskog A; Lundin J; Glimelius B; Melbye M; Juliusson G; Jurlander J; Rosenquist R
Leuk Res; 2010 Mar; 34(3):335-9. PubMed ID: 19573916
[TBL] [Abstract] [Full Text] [Related]
6. mdm2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract] [Full Text] [Related]
7. Nucleophosmin gene mutations in acute myeloid leukemia.
Chen W; Rassidakis GZ; Medeiros LJ
Arch Pathol Lab Med; 2006 Nov; 130(11):1687-92. PubMed ID: 17076533
[TBL] [Abstract] [Full Text] [Related]
8. p53 and mdm2 in mantle cell lymphoma in leukemic phase.
Solenthaler M; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
Haematologica; 2002 Nov; 87(11):1141-50. PubMed ID: 12414343
[TBL] [Abstract] [Full Text] [Related]
9. The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.
Faderl S; Kantarjian HM; Manshouri T; Chan CY; Pierce S; Hays KJ; Cortes J; Thomas D; Estrov Z; Albitar M
Clin Cancer Res; 1999 Jul; 5(7):1855-61. PubMed ID: 10430092
[TBL] [Abstract] [Full Text] [Related]
